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Edited by Frances ShannonAbstract ISG15, an interferon-upregulated ubiquitin-like pro-
tein, is covalently conjugated to various cellular proteins (ISGy-
lation). In this study, we found that protein phosphatase 2Cb
(PP2Cb), which functions in the nuclear factor jB (NF-jB)
pathway via dephosphorylation of TGF-b-activated kinase, was
ISGylated, and analysis by NF-jB luciferase reporter assay re-
vealed that PP2Cb activity was suppressed by co-expression of
ISG15, UBE1L, and UbcH8. We determined the ISGylation
sites of PP2Cb and constructed its ISGylation-resistant mutant.
In contrast to the wild type, this mutant suppressed the NF-jB
pathway even in the presence of ISG15, UBE1L, and UbcH8.
Thus, we propose that ISGylation negatively regulates PP2Cb
activity.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Interferon-stimulated gene 15 kDa; Interferon;
Ubiquitin; Protein phosphatase; Nuclear factor jB1. Introduction
Interferon (IFN) is a pleiotropic cytokine that has an
essential role in cellular antiviral response through inducing
interferon-stimulated genes (ISGs) [1]. ISG15, one of the
ISGs, is a ubiquitin-like protein that is covalently conjugated
to various cellular proteins (ISGylation) upon interferon
stimuli [2]. This protein functions as an antiviral protein
against Sindbis virus and HIV-1 [3,4] and as a suppressor
of the ubiquitin–proteasome system [5]. Although various tar-
get proteins for ISGylation have been identiﬁed by a proteo-
mic approach [6–8] and a cascade of the protein ISGylation
system has become clear [9–14], the biological consequences
of ISGylation of target proteins have been studied in only
a few cases [15–17].
Protein phosphatase 2Cb (PP2Cb) is an enzyme that belongs
to the PP2C type protein phosphatase family and functions as
a monomer [18]. PP2Cb dephosphorylates and suppresses
TGF-b-activated kinase (TAK1) and IjB kinase (IKK), both
of which have essential roles in the nuclear factor jB (NF-
jB) pathway, an important pathway functioning in innate
immunity, adaptive immunity, and cancer [19–22].Abbreviations: ISG15, interferon-stimulated gene 15 kDa; E1, ubiqui-
tin-activating enzyme; E2, ubiquitin-conjugating enzyme; PP2Cb, pr-
otein phosphatase 2Cb; TAK1, TGF-b-activated kinase; TAB1,
TAK1-binding protein; NF-jB, nuclear factor jB; IjB, inhibitor of
NF-jB; IKK, IjB kinase; IFN, interferon
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doi:10.1016/j.febslet.2006.07.032We previously reported that ISGylation of UbcH6 and
Ubc13 suppresses their ubiquitin E2 enzyme activities [16,17].
In a search for ISGylated proteins, we identiﬁed PP2Cb as a
target protein for ISGylation. In addition, we found that
ISGylation of PP2Cb suppresses the activity of PP2Cb against
TAK1-induced NF-jB activation.2. Materials and methods
2.1. Cell culture and transfection
HeLa cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
(Sigma) supplemented with 10% heat-inactivated calf serum (Hyclone).
Transfection was performed according to the standard calcium precip-
itation protocol.
2.2. Plasmid construction
The mammalian expression plasmids of ISG15, UBE1L, and
UbcH8 were generated as described previously [17]. The open-read-
ing frames of human PP2Cb, TAK1, and TAK1-binding protein
(TAB1) were ampliﬁed by PCR. Deletion and point mutants of
PP2Cb were generated by PCR. All constructs were veriﬁed by
DNA sequencing. To generate mammalian expression plasmids of
C-terminally and N-terminally Flag-tagged PP2Cb, the PCR frag-
ment was subcloned into pCI-neo-C3Flag and pCI-neo-3Flag vec-
tors, respectively, which had been generated by inserting three
repeats of Flag tag sequence into the pCI-neo mammalian expression
vector (Promega). To generate the mammalian expression plasmids
of TAK1 and TAB1, the PCR fragments were subcloned into the
pCI-neo-2S and pCI-neo-5HA vectors that had been generated by
inserting oligonucleotides encoding two repeats of S peptide sequence
and ﬁve repeats of HA tag sequence, respectively, into the pCI-neo
mammalian expression vector.
2.3. Immunoprecipitation and Western blotting
HeLa cells that had been transiently transfected with indicated plas-
mids and cultured for 24–30 h were lysed with RIPA buﬀer containing
50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% sodium
deoxycholate, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl ﬂuoride
and 5 mM N-ethylmaleimide, and the supernatant of the cell lysate
was subjected to immunoprecipitation and then to Western blotting
with various antibodies as described previously [16,17] except for
anti-PP2Cb [19] and anti-IjBa (BD Biosciences) antibodies. The eﬀect
of IFN treatment was analyzed as described previously [17] except for
HeLa cells and lysis buﬀer containing 20 mM Tris–HCl, pH 7.5,
150 mM NaCl, 1% Triton X-100, 5 mM EDTA, 1 mM phenylmethyl-
sulfonyl ﬂuoride, and 5 mM N-ethylmaleimide.
2.4. Reporter gene assay
HeLa cells were transfected with the pNF-jB-Luc reporter plasmid
(BD Biosciences) and indicated plasmids, together with pRL-TK (Pro-
mega) for normalizing transfection eﬃciency. Twenty-four hours after
transfection, cells were lysed and luciferase activity was measured by
using a Dual-Luciferase Reporter Assay System (Promega) and an
AB-2000 luminescencer-PSN (Atto, Tokyo, Japan). The same experi-
ments were repeated three times.blished by Elsevier B.V. All rights reserved.
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3.1. PP2Cb is modiﬁed with ISG15
To identify proteins modiﬁed with ISG15, we carried out a
proteomic analysis of ISGylated proteins. We expressed
Flag-tagged ISG15, S-tagged UBE1L (E1), and S-tagged
UbcH8 (E2) in HeLa cells, and ISGylated proteins were iso-
lated by immunoprecipitation with anti-Flag antibody and
subjected to peptide mass ﬁngerprinting. We identiﬁed several
novel ISGylated proteins (data not shown; data to be pre-
sented elsewhere). Among them, we focused on PP2Cb because
PP2Cb dephosphorylates and suppresses TAK1 and IKK, ki-
nases both functioning in the NF-jB pathway [19,20].
To conﬁrm ISGylation of PP2Cb, we expressed Flag-tagged
PP2Cb together with T7-tagged ISG15, S-tagged UBE1L and
S-tagged UbcH8 in HeLa cells, and the extract of transfected
cells was subjected to immunoprecipitation with anti-Flag
tag antibody and then to Western blotting with anti-T7 tag
and anti-Flag tag antibodies (Fig. 1). Two bands (the molecu-
lar masses of 88 and 110 kDa) with slower mobilities than that
of intact PP2Cb (67 kDa) were detected by anti-Flag tag anti-
body in UBE1L- and UbcH8-dependent manners and these
bands were also detected by anti-T7 tag antibody: The above
diﬀerence in molecular masses between modiﬁed and intact
ones is reasonably thought to be due to ISGylation. These re-
sults strongly suggest that PP2Cb is covalently modiﬁed with
ISG15, the conjugation being mediated by UBE1L and
UbcH8. It should be noted that ISGylation of various proteins
was detected by overexpression of UBE1L in the presence of
ISG15 and was further enhanced by co-expression of UBE1L
and UbcH8 (Fig. 1, left panel): These results are consistent
with the previous report [11].
Next, to conﬁrm that PP2Cb is ISGylated in response to IFN
signal, HeLa cells that had expressed Flag-tagged PP2Cb were
treated with IFNb. The cell extract was subjected to immuno-
precipitation with anti-Flag tag antibody and then to Western
blotting with anti-Flag tag and anti-ISG15 antibodies
(Fig. 2A). In another experiment (Fig. 2B), the extract of HeLaFig. 1. PP2Cb is covalently modiﬁed with ISG15. The extracts of HeLa ce
subjected to Western blotting with anti-T7 tag and anti-S peptide antibodies
then to Western blotting with anti-Flag tag and anti-T7 tag antibodies (right
speciﬁc bands are indicated by asterisks.cells that had been treated with IFNb was subjected to immu-
noprecipitation with anti-PP2Cb antibody and then to Western
blotting with anti-PP2Cb and anti-ISG15 antibodies. In both
experiments, two bands due to ISGylated PP2Cb were detected
only in the case of IFN treatment, indicating that PP2Cb is
ISGylated in response to IFN signal under physiological condi-
tions. ISGylation of various proteins was also detected only in
the case of IFN treatment (Fig. 2A and B, right panels). It
should be noted that the molecular mass (67 kDa) of exoge-
nously expressed Flag-tagged PP2Cb isoform 1, the longest iso-
form of human PP2Cb [23] and the isoform used in this study, is
diﬀerent from that (42 kDa) of endogenous PP2Cb isoform 2,
the most abundant isoform in HeLa cells [24].
3.2. PP2Cb activity is suppressed by addition of a protein
ISGylation system
It has been reported that PP2Cb dephosphorylates and sup-
presses TAK1 [19], which functions in the NF-jB pathway to-
gether with TAB1 [25]. We therefore carried out an experiment
to determine whether a protein ISGylation system modulates
PP2Cb activity against TAK1/TAB1-induced NF-jB activa-
tion. HeLa cells were co-transfected with plasmids of HA-
tagged TAK1 and TAB1, Flag-tagged PP2Cb, and ISGylation
system (T7-tagged ISG15, S-tagged UBE1L, and S-tagged
UbcH8), together with NF-jB luciferase reporter plasmid,
and luciferase activity was measured (Fig. 3). PP2Cb sup-
pressed TAK1/TAB1-induced NF-jB activation in the absence
of the ISGylation system but not in the presence of the ISGy-
lation system. It should be noted that TAB1 alone has little ef-
fect [25]. These results suggest that ISGylation of PP2Cb
suppresses the activity of PP2Cb against TAK1/TAB1-induced
NF-jB activation.
3.3. PP2Cb is modiﬁed with ISG15 at least through Lys12 and
Lys142
To conﬁrm the above assumption, it is necessary to con-
struct an ISGylation-resistant mutant of PP2Cb. Since PP2Cb
is expected to be ISGylated through at least two Lys residueslls that had been transiently transfected with indicated plasmids were
(left panel) or to immunoprecipitation with anti-Flag tag antibody and
panel). The ISGylated PP2Cb is indicated by an open arrowhead. Non-
Fig. 2. PP2Cb is ISGylated in response to IFN signal. (A) The extract of HeLa cells that had been transiently transfected with Flag-tagged PP2Cb
expression plasmid, followed by 24-h treatment with IFNb (1000 units/ml) (Pepro Tech), was subjected to immunoprecipitation with anti-Flag tag
antibody and then to Western blotting with anti-Flag tag and anti-ISG15 antibodies. (B) The extract of HeLa cells pretreated with IFNb was
subjected to immunoprecipitation with anti-PP2Cb antibody and control immunoglobulin (Ig) and then to Western blotting with anti-PP2Cb and
anti-ISG15 antibodies.
Fig. 3. ISGylation system suppresses PP2Cb activity. HeLa cells were
transiently transfected with indicated plasmids together with pNF-jB
reporter plasmid and were then lysed, and luciferase activity was
measured. Results are expressed as fold induction in luciferase activity
relative to that of control mocked cells that had been transfected with
an empty vector. Triple experiments were carried out, and the error
bars represent standard deviation. The ISGylation system contains T7-
tagged ISG15, S-tagged UBE1L, and S-tagged UbcH8.
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tants and expressed them together with the above ISGylation
system in HeLa cells. The extract of transfected cells was sub-
jected to immunoprecipitation with anti-Flag tag antibody and
then to Western blotting with anti-Flag tag and anti-T7 tag
antibodies (Fig. 4). PP2Cb D296–479 was modiﬁed with
ISG15 to an extent similar to that in the case of the wild type,
while PP2Cb D1–295 was not modiﬁed with ISG15 (Fig. 4A)
and PP2Cb D1–92 and D93–193 seemed to be less modiﬁed
(Fig. 4B). We hypothesized that one of the Lys residues mod-
iﬁed with ISG15 is located in the sequence 1–92, while anotheris in 93–193. We next constructed various PP2Cb mutants in
which the Lys residues had been changed to Arg, measured
their levels of ISGylation, and found that PP2Cb K12R was
less modiﬁed with ISG15 than was the wild type (data not
shown). We ﬁnally constructed various PP2Cb KR mutants
in which the two Lys residues had been changed to Arg and
analyzed their levels of ISGylation (Fig. 5). PP2Cb
K12,142R was barely modiﬁed with ISG15 in either the case
of N-terminally (Fig. 5A) or C-terminally Flag-tagged PP2Cb
(Fig. 5B). Thus, we concluded that PP2Cb is modiﬁed with
ISG15 at least through Lys12 and Lys142.
3.4. PP2Cb activity is suppressed by ISG15 conjugation
Using the PP2Cb K12,142R mutant as an ISGylation-resis-
tant mutant, we performed an NF-jB luciferase reporter assay
as described above (see Fig. 3). As shown in Fig. 6A, in the ab-
sence of the ISGylation system, the wild type (Wt) and the
K12,142R (KR) mutant suppressed TAK1/TAB1-induced
NF-jB activation, while in the presence of the ISGylation sys-
tem, the wild type had little suppressive eﬀect as shown above
(see Fig. 3), but the K12,142R mutant had a suppressive eﬀect.
It should be noted that the ISGylation system alone has little
eﬀect (data not shown). These results suggest that ISGylation
of PP2Cb suppresses its activity.
Since degradation of IjBa by the ubiquitin–proteasome sys-
tem is essential for activation of NF-jB [26–28], we next carried
out an experiment to clarify the eﬀect of ISGylation of PP2Cb
on IjBa degradation. We expressed Flag-tagged wild-type
PP2Cb or its K12,142R mutant, S-tagged TAK1 and TAB1,
and the ISGylation system in HeLa cells, and the cells were then
treated with cycloheximide (CHX), a protein synthesis inhibi-
tor, for 30 min. The cell extract was subjected to Western blot-
ting with anti-IjBa, anti-Flag tag, anti-S peptide, and anti-T7
tag antibodies (Fig. 6B). In our assay conditions, in the absence
Fig. 4. ISGylation of PP2Cb deletion mutants. The extracts of HeLa cells expressing the wild type PP2Cb and its various deletion mutants, (A) D1–
295 and D296–479 and (B) D1–92, D93–193, D194–295, D296–378 and D379–479, in the presence and absence of the ISGylation system were subjected
to immunoprecipitation with anti-Flag tag antibody and then to Western blotting with anti-Flag tag and anti-T7 tag antibodies.
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changed in all combinations of expression plasmids. However,
when the cells had been treated with cycloheximide, the level of
IjBa in the case of wild-type PP2Cb was less than that in the
case of the K12,142R mutant in the presence of the ISGylation
system. It should be noted that the ISGylation system alone has
little eﬀect (data not shown). These results imply that ISGylated
PP2Cb has a less suppressive eﬀect on TAK1/TAB1-induced
degradation of IjBa than the ISGylation-resistant mutant
does, supporting the above assumption that ISGylation of
PP2Cb suppresses its activity.Fig. 5. ISGylation of PP2Cb KR mutants. The extracts of HeLa cells ex
terminally Flag-tagged (B), in the presence of the ISGylation system were subjIn conclusion, we found that PP2Cb is covalently modiﬁed
with ISG15 in an IFN-dependent manner and that ISGylation
of PP2Cb suppresses the activity of PP2Cb against TAK1/
TAB1-induced IjBa degradation and NF-jB activation. It
can be inferred that the activity of ISGylated PP2Cb is less than
that of the original one. The construction of an in vitro assay
system will clarify this point and is our future project. Consid-
ering that TAK1 is indispensable for cellular responses to vari-
ous stimuli, including interleukin-1, tumor necrosis factor-a,
and a toll-like receptor ligand [25,29], it can be inferred that
ISGylation of PP2Cb has an eﬀect on various cellular responses.pressing various KR mutants, N-terminally Flag-tagged (A) and C-
ected to immunoprecipitation and then to Western blotting as in Fig. 4.
Fig. 6. ISGylation of PP2Cb suppresses its activity. (A) HeLa cells were transiently transfected with indicated plasmids together with pNF-jB
reporter plasmid, and luciferase activity was measured as in Fig. 3. (B) The extracts of HeLa cells that had been transiently transfected with indicated
plasmids and then treated with cycloheximide (CHX) (50 lg/ml) for 30 min were subjected to Western blotting with anti-IjBa, anti-Flag tag, anti-S
peptide, and anti-T7 tag antibodies. Wt, wild type; KR, K12,142R.
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